Sign In
Buy RGEN
$121.73
+0.600 (+0.495%)
At Close: Jun 03, 2026
Repligen to Report Third Quarter 2021 Financial Results
07:30am, Thursday, 14'th Oct 2021
Webcast and Conference Call to Be Held Thursday, October 28, 2021 at 8:30 a.m. EDT
What's Next For Repligen Stock After A 12% Fall In A Month?
09:15am, Tuesday, 12'th Oct 2021
The stock price of Repligen (NASDAQ: RGEN), a U.S.-based life sciences company involved in production of materials used in the manufacture of biological drugs, has seen a 12% drop over the last twenty
Repligen Reinforces Proteins Business With $150M Avitide Acquisition Deal
01:08pm, Thursday, 16'th Sep 2021
Repligen Corporation (NASDAQ: RGEN) has agreed to acquire privately-held Avitide Inc for approximately $150 million in cash and stock. The deal consideration includes $75 million in cash plus $75 mill
Repligen Announces Agreement to Acquire Avitide Inc.
07:40am, Thursday, 16'th Sep 2021
WALTHAM, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into
Repligen and Navigo GmbH Announce Launch of Industry-First Protein A Ligand for Purification of pH Sensitive Antibodies
07:30am, Thursday, 09'th Sep 2021
WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and Navigo Proteins GmbH (“Navigo”),
Repligen Senior VP Makes $1.13 Million Sell
01:36pm, Thursday, 02'nd Sep 2021
Ralf Kuriyel, Senior VP and RD at Repligen (NASDAQ:RGEN), made a large insider sell on August 30, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Co
CARA Drug Wins FDA Nod for Pruritus Associated With CKD
12:59pm, Tuesday, 24'th Aug 2021
CARA gets a significant boost with FDA approval for Korsuva injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis.
Repligen: Set Recurring Investments To Sleep Well And Help Cure Diseases
10:09am, Tuesday, 03'rd Aug 2021
Repligen is one of those prime companies that let you sleep well at night with a long history of stable performance. The company has shown 30% revenue growth over the past decade, and will lift the tr
Why Repligen Stock Soared This Week
06:11am, Friday, 30'th Jul 2021
The life sciences company reported better-than-expected second-quarter results.
Repligen (RGEN) Beats on Q2 Earnings & Sales, Ups 2021 View
11:25am, Wednesday, 28'th Jul 2021
Repligen (RGEN) reports encouraging second-quarter results, with sales and earnings beating estimates. The company also raises its guidance for 2021.
Repligen Corp, Inc. (RGEN) CEO Anthony Hunt on Q1 2021 Results - Earnings Call Transcript
11:13am, Tuesday, 27'th Jul 2021
Repligen Corp, Inc. (RGEN) CEO Anthony Hunt on Q1 2021 Results - Earnings Call Transcript
Recap: Repligen Q2 Earnings
07:42am, Tuesday, 27'th Jul 2021
Shares of Repligen (NASDAQ:RGEN) moved higher by 0.0% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 88.10% over the past year to $0.79, whic
Repligen Reports Second Quarter 2021 Financial Results and Updates Full Year 2021 Financial Guidance
07:30am, Tuesday, 27'th Jul 2021
WALTHAM, Mass., July 27, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its s
Earnings Outlook For Repligen
10:37am, Monday, 26'th Jul 2021
Repligen (NASDAQ:RGEN) announces its next round of earnings this Tuesday, July 27. Here is Benzinga's everything-that-matters guide for this Tuesday's Q2 earnings announcement.
Repligen to Report Second Quarter 2021 Financial Results
07:30am, Tuesday, 13'th Jul 2021
Webcast and Conference Call to Be Held Tuesday, July 27, 2021 at 8:30 a.m. EDT Webcast and Conference Call to Be Held Tuesday, July 27, 2021 at 8:30 a.m. EDT
